Skip to content
An Initiative of AVAC
Search
Back to Events

The Scientific Journey of Lenacapavir: From basic science to clinical development to impact

Wednesday11June
15:00 - 16:30 GMT
Virtual

Join us for the compelling story of the development of lenacapavir and the critical role of US support. Wes Sundquist, from the University of Utah, will share the story of capsid inhibitor discovery; and Linda-Gail Bekker, from the Desmond Tutu HIV Foundation, will discuss the critical role of South Africa in clinical development; all of this work, backed by long-term US support.

Topic(s): Research

Product(s): Lenacapavir

Source(s): AVAC

Register Now

Featured Resources

External Link

HIVR4P 2024 Knowledge Toolkit

The HIVR4P 2024 Knowledge Toolkit highlights important scientific advancements and innovative research across key thematic areas presented at the HIVR4P 2024 conference. Thematic areas include the PURPOSE 2 trial of long-acting lenacapavir for PrEP, data on the three-month dapivirine vaginal ring, and early evidence on offering a choice of PrEP methods.
External Link

Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs

This article from Journal of Addiction Medicine examines interests and concerns around use of oral and injectable PrEP amongst people who inject drugs in the United States.
Document

Long-Acting PrEP for Key Populations: Considerations for Implementation

This document is intended for program implementers, advocates, policymakers, and other stakeholders who influence the rollout of long-acting options for pre-exposure prophylaxis (PrEP). It highlights some of the considerations for long-acting PrEP implementation for key population individuals.
Document

Gears of Lenacapavir for PrEP Rollout

This report provides a framework for accelerated and equitable introduction of injectable lenacapavir (LEN) for PrEP, including outlining priority actions for different stakeholder groups.
External Link

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

This article from the New England Journal of Medicine describes the results of PURPOSE 2, the Phase III clinical trial for injectable lenacapavir for PrEP, carried out amongst gay and bisexual men who have sex with men, trans men, trans women, and gender non binary individuals in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and…
Document

From Clinical Trial Efficacy to Public Health Impact: A plan for accelerating access to injectable lenacapavir for PrEP

This plan provides a comprehensive view of all the moving parts for lenacapavir for PrEP introduction and identifies priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered.
Spreadsheet

Access Workbook for Cabotegravir for PrEP, Dapivirine Vaginal Ring, and Lenacapavir for PrEP

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP, the dapivirine vaginal ring (DVR), and lenacapavir (LEN) for PrEP for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit…
External Link

Expanding Access to Lenacapavir

This United Advocates Network Call, titled Breaking New Ground: Expanding Access to Lenacapavir— Lessons from Dolutegravir and the Future of HIV Prevention, brought together global health experts, community advocates, and civil society organizations to discuss the challenges and opportunities in ensuring equitable access to Lenacapavir.
External Link

Health Impact, Budget Impact, and Price Threshold for Cost-effectiveness of Lenacapavir for HIV Pre-exposure Prophylaxis in Eastern and Southern Africa: A modelling analysis

This article from The Lancet HIV describes the use of the EMOD-HIV model to estimate the health and budget impacts and threshold price at which lenacapavir for PrEP could be cost-effective in eastern and southern Africa.
Document

The Long Wait for Long-acting HIV Prevention and Treatment Formulations

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.